公开(公告)号：PL369867A1

公开(公告)日：2005-05-02

申请号：PL36986702

申请日：2002-10-16

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: A61K31/4365 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P5/14 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D495/04

Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis

公开(公告)号：NO20050306A

公开(公告)日：2005-03-16

申请号：NO20050306

申请日：2005-01-19

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: A61K31/4743 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D495/04 ,  A61K31/44

CPC classification number: C07D495/04

公开(公告)号：CA2528603A1

公开(公告)日：2004-12-29

申请号：CA2528603

申请日：2004-06-18

Applicant: CELLTECH R&D LTD

Inventor： LANGHAM BARRY JOHN ,  DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER

IPC: C07D495/04 ,  A61K31/4365 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  C07D221/00 ,  C07D333/00

Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2 - position by a carbonyl- or sulfonyl-linked pyrrolidin-3-yl, pyrrolidin-3- ylamino or related moiety, being inhibitors of p38 MAP kinase, are according ly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

公开(公告)号：CA2500844A1

公开(公告)日：2004-04-15

申请号：CA2500844

申请日：2003-09-30

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  LANGHAM BARRY JOHN ,  CUBBON RACHEL JANE ,  BROOKINGS DANIEL CHRISTOPHER

IPC: A61P19/00 ,  A61P29/00 ,  A61P37/00 ,  C07D471/04 ,  A61K31/437

Abstract: A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorde rs.

公开(公告)号：AU5088900A

公开(公告)日：2000-12-18

申请号：AU5088900

申请日：2000-05-26

Applicant: CELLTECH R&D LTD

Inventor： LANGHAM BARRY JOHN ,  ALEXANDER RIKKI PETER ,  HEAD JOHN CLIFFORD ,  LINSLEY JANEEN MARSHA ,  PORTER JOHN ROBERT ,  ARCHIBALD SARAH CATHERINE ,  WARRELOW GRAHAM JOHN

IPC: A61K31/198 ,  A61K31/223 ,  A61K31/381 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/472 ,  A61K31/505 ,  A61P7/00 ,  A61P29/00 ,  A61P37/00 ,  A61P43/00 ,  C07B61/00 ,  C07C229/34 ,  C07C229/36 ,  C07C233/55 ,  C07C233/81 ,  C07C235/16 ,  C07C235/24 ,  C07C235/56 ,  C07C235/64 ,  C07C235/84 ,  C07C237/40 ,  C07C255/57 ,  C07C271/22 ,  C07C271/28 ,  C07C271/58 ,  C07D213/79 ,  C07D213/81 ,  C07D215/42 ,  C07D217/22 ,  C07D239/34 ,  C07D239/42 ,  C07D239/88 ,  C07D239/94 ,  C07D241/42 ,  C07D241/44 ,  C07D295/135 ,  C07D333/40 ,  C07D333/70 ,  C07D471/04 ,  C07D295/12 ,  A61K31/122 ,  A61K31/44

Abstract: Squaric acid Derivatives of formula (1) are described: wherein R1 is an integrin binding group; R2 is a hydrogen atom or a C1-6alkyl group; L1 is a covalent bond or a linker atom or group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic chain; R3 is a hydrogen atom or an optionally substituted heteroaliphatic, cycloaliphatic, heterocycloaliphatic, polycycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group: and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune of inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.

公开(公告)号：BRPI0410653A

公开(公告)日：2006-07-04

申请号：BRPI0410653

申请日：2004-06-18

Applicant: CELLTECH R&D LTD

Inventor： BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  LANGHAM BARRY JOHN

IPC: A61P29/00 ,  C07D495/04 ,  A61K31/4365

Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-1-yl or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

公开(公告)号：NZ537740A

公开(公告)日：2006-03-31

申请号：NZ53774003

申请日：2003-06-20

Applicant: CELLTECH R&D LTD

Inventor： BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  LANGHAM BARRY JOHN

IPC: A61K31/4743 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D495/04 ,  A61K31/44

Abstract: Disclosed are compounds of the formula (I), wherein The dashed line joining A and C(Ra) is present and represents a bond, and A is a ûC(Rb)= group, or the dashed line is absent and A is a ûC(Rb)(Rc)- group; R is H or a straight or branched C1-6- alkyl group; X is an ûO- or ûS- atom; Y is a N or substituted C atom or a ûCH= group; N is 0 or 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain; L1 is a covalent bond or a linker atom or group; Cy1 is a H or an optionally a substituted cycloaliphatic, poly cycloaliphatic, hetereocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; And the salts, solvates, hydrates and N-oxides thereof. Further disclosed are pharmaceutical compositions comprising a compound of formula (I); and the use of one of the compounds of the invention for the manufacture of a medicament for the treatment of rheumatoid arthritis.

公开(公告)号：NO20041975L

公开(公告)日：2005-07-16

申请号：NO20041975

申请日：2004-05-13

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: A61K31/4365 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P5/14 ,  A61P7/02 ,  A61P7/06 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/14 ,  A61P31/18 ,  A61P31/20 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D471/04 ,  C07D495/04

Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis

公开(公告)号：IS7652A

公开(公告)日：2005-01-18

申请号：IS7652

申请日：2005-01-18

Applicant: CELLTECH R&D LTD

Inventor： BROOKINGS DANIEL CHRISTOPHER ,  DAVIS JEREMY MARTIN ,  LANGHAM BARRY JOHN

IPC: A61K31/4743 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P7/04 ,  A61P7/06 ,  A61P9/10 ,  A61P11/00 ,  A61P11/06 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P19/08 ,  A61P19/10 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P31/00 ,  A61P31/12 ,  A61P31/16 ,  A61P31/22 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D495/04 ,  A61K31/44

公开(公告)号：AU2004249498A1

公开(公告)日：2004-12-29

申请号：AU2004249498

申请日：2004-06-18

Applicant: CELLTECH R&D LTD

Inventor： DAVIS JEREMY MARTIN ,  BROOKINGS DANIEL CHRISTOPHER ,  LANGHAM BARRY JOHN

IPC: C07D495/04 ,  A61K31/4365 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  C07D221/00

Abstract: A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-3-yl, pyrrolidin-3-ylamino or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.